| Index | S&P 500 | P/E | 50.26 | EPS (ttm) | 5.36 | Insider Own | 3.26% | Shs Outstand | 151.00M | Perf Week | 2.62% |
| Market Cap | 40.68B | Forward P/E | 44.19 | EPS next Y | 6.10 | Insider Trans | -62.34% | Shs Float | 150.48M | Perf Month | -1.64% |
| Enterprise Value | 41.96B | PEG | 3.58 | EPS next Q | - | Inst Own | 78.33% | Short Float | 6.29% | Perf Quarter | 42.20% |
| Income | 825.00M | P/S | 9.05 | EPS this Y | 13.20% | Inst Trans | 0.00% | Short Ratio | 3.63 | Perf Half Y | 110.68% |
| Sales | 4.49B | P/B | 14.33 | EPS next Y | 13.84% | ROA | 12.41% | Short Interest | 9.47M | Perf YTD | 105.41% |
| Book/sh | 18.79 | P/C | 34.83 | EPS next 5Y | 14.02% | ROE | 31.08% | 52W High | 309.36 -12.91% | Perf Year | 177.10% |
| Cash/sh | 7.74 | P/FCF | 43.33 | EPS past 3/5Y | - 4.23% | ROIC | 13.54% | 52W Low | 94.00 186.62% | Perf 3Y | 122.77% |
| Dividend Est. | - | EV/EBITDA | 30.78 | Sales past 3/5Y | -1.82% 6.02% | Gross Margin | 66.79% | Volatility | 5.79% 5.29% | Perf 5Y | -32.37% |
| Dividend TTM | - | EV/Sales | 9.34 | EPS Y/Y TTM | 169.70% | Oper. Margin | 20.97% | ATR (14) | 14.20 | Perf 10Y | 102.10% |
| Dividend Ex-Date | - | Quick Ratio | 1.40 | Sales Y/Y TTM | 2.77% | Profit Margin | 18.36% | RSI (14) | 54.66 | Recom | 2.56 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.80 | EPS Q/Q | 10.08% | SMA20 | -0.88% | Beta | 1.42 | Target Price | 252.73 |
| Payout | 0.00% | Debt/Eq | 0.91 | Sales Q/Q | 9.65% | SMA50 | 11.42% | Rel Volume | 0.45 | Prev Close | 269.40 |
| Employees | 8,600 | LT Debt/Eq | 0.73 | Earnings | Oct 29 | SMA200 | 55.83% | Avg Volume | 2.81M | Price | 269.42 |
| IPO Date | Jul 28, 2000 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 6.82% 2.51% | Net Debt/EBITDA | 1.09 | Volume | 1,262,482 | Change | 0.01% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-23-26 | Reiterated | Stephens | Overweight | $110 → $275 |
| Oct-19-26 | Reiterated | Canaccord Genuity | Hold | $205 → $300 |
| Oct-07-26 | Reiterated | Barclays | Underweight | $160 → $200 |
| Oct-01-26 | Reiterated | Guggenheim | Buy | $226 → $305 |
| Sep-29-26 | Reiterated | Leerink Partners | Outperform | $210 → $300 |
| Sep-28-26 | Reiterated | Piper Sandler | Overweight | $170 → $305 |
| Sep-09-26 | Upgrade | UBS | Neutral → Buy | $135 → $260 |
| Sep-03-26 | Reiterated | Argus Research | Buy | $150 → $235 |
| Aug-03-26 | Reiterated | Canaccord Genuity | Hold | $190 → $205 |
| Jul-31-26 | Reiterated | Bernstein | $185 → $215 |
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/28/2025 | FY 2024 12/29/2024 | FY 2023 12/31/2023 | FY 2022 1/1/2023 | FY 2021 1/2/2022 | FY 2020 1/3/2021 | FY 2019 12/29/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 4,493 | 4,338 | 4,372 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 1,492 | 1,445 | 1,511 | — | — | — | — | — | — | |
| Gross Profit | 3,001 | 2,893 | 2,861 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 1,101 | 1,078 | 1,092 | — | — | — | — | — | — | |
| Research and Development | 958 | 951 | 1,169 | — | — | — | — | — | — | |
| Other Operating Expense | 0 | 0 | 1,433 | — | — | — | — | — | — | |
| Operating Income | 942 | 864 | -833 | — | — | — | — | — | — | |
| Interest Expense | 75 | 101 | 100 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 148 | 323 | -246 | — | — | — | — | — | — | |
| Net Income Before Taxes | 1,015 | 1,086 | -1,179 | — | — | — | — | — | — | |
| Income Taxes | 190 | 236 | 44 | — | — | — | — | — | — | |
| Consolidated Net Income | 825 | 850 | -1,223 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 825 | 850 | -1,223 | — | — | — | — | — | — | |
| Net Income | 825 | 850 | -1,223 | — | — | — | — | — | — | |
| EPS (Recurring) | 5.41 | 5.48 | -7.69 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 5.41 | 5.48 | -7.69 | — | — | — | — | — | — | |
| EPS (Diluted) | 5.36 | 5.45 | -7.69 | — | — | — | — | — | — | |
| EBITDA | 1,363 | 1,457 | -725 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 50.26 | 24.76 | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 9.05 | 4.82 | 4.92 | — | — | — | — | — | — | |
| Gross Margin | 66.79 | 66.69 | 65.44 | — | — | — | — | — | — | |
| Operating Margin | 20.97 | 19.92 | -19.05 | — | — | — | — | — | — | |
| Net Margin | 18.36 | 19.59 | -27.97 | — | — | — | — | — | — | |
| Shares Outstanding | 151 | 155 | 159 | — | — | — | — | — | — | |
| Market Capitalization | 40,682 | 20,917 | 21,508 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Meister Keith A. | Director | Sep 04 '26 | Sale | 218.40 | 119,501 | 26,098,466 | 770,350 | Sep 04 |
| Meister Keith A. | Director | Sep 03 '26 | Sale | 218.23 | 75,951 | 16,574,482 | 889,851 | Sep 04 |
| Meister Keith A. | Director | Sep 02 '26 | Sale | 213.28 | 68,108 | 14,526,255 | 965,802 | Sep 04 |
| Meister Keith A. | Director | Aug 27 '26 | Sale | 228.89 | 138,379 | 31,673,778 | 1,033,910 | Aug 27 |
| Meister Keith A. | Director | Aug 26 '26 | Sale | 225.46 | 106,543 | 24,021,247 | 1,172,289 | Aug 27 |
| Meister Keith A. | Director | Aug 25 '26 | Sale | 225.51 | 131,019 | 29,546,639 | 1,278,832 | Aug 27 |
| Meister Keith A. | Director | Aug 21 '26 | Sale | 217.96 | 299,336 | 65,243,447 | 1,409,851 | Aug 21 |
| Meister Keith A. | Director | Aug 20 '26 | Sale | 213.86 | 285,238 | 61,000,126 | 1,709,187 | Aug 21 |
| Meister Keith A. | Director | Aug 19 '26 | Sale | 203.29 | 95,000 | 19,312,826 | 1,994,425 | Aug 21 |
| Wedel Christensen Jakob | SVP, Strategy/Corp Development | Aug 18 '26 | Sale | 191.52 | 1,033 | 197,840 | 14,023 | Aug 20 |
| Meister Keith A. | Director | Aug 05 '26 | Sale | 199.61 | 283,269 | 56,543,332 | 2,089,425 | Aug 06 |
| Meister Keith A. | Director | Aug 04 '26 | Sale | 200.10 | 457,858 | 91,616,565 | 2,372,694 | Aug 06 |
| Davies Scott M | Chief Legal Officer | Jul 30 '26 | Sale | 200.00 | 615 | 123,000 | 20,338 | Aug 03 |
| Davies Scott M | Chief Legal Officer | Jun 25 '26 | Sale | 180.00 | 615 | 110,700 | 20,953 | Jun 25 |
| Leckman Patricia | SVP, Chief People Officer | Jun 05 '26 | Sale | 162.59 | 783 | 127,305 | 21,259 | Jun 09 |